Breast CancersMDCTNCT06856876
Examining the Effectiveness of Multidisciplinary Care Teams in Improving Outcomes for Breast Cancer Patients
A study testing Multidisciplinary Care Team (MDCT) Approach and Standard Breast Cancer Therapy in people with Breast Cancers and Breast Cancer Female, run by Yousaf Jan at 1 site in Pakistan.
Trial summary
To compare clinical outcomes, patient-reported measures (PROMs), and healthcare utilization between standard care with or without an MDCT in a cohort of women treated for breast cancer. Read more about this study
- Who is it for?
- Ages 18 to 70 years, women only
- Conditions the study is for
- Breast Cancers, Breast Cancer Female, Breast Cancer Stage I
- What is being tested?
- Multidisciplinary Care Team (MDCT) Approach and Standard Breast Cancer Therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 73 participants
- Where
- 1 sitePakistan
- Study dates
- 1 May 2021to 30 Apr 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All female patients, diagnosed with breast cancer
Who cannot join
- Previous treatment for breast cancer, concurrent enrollment in another clinical research, and serious medical conditions that could affect study outcomes
Trial locations and contacts
1 site in 1 country.
About this study
To compare clinical outcomes, patient-reported measures (PROMs), and healthcare utilization between standard care with or without an MDCT in a cohort of women treated for breast cancer.
Read the detailed description
This single-center, prospective interventional trial evaluates the effectiveness of Multidisciplinary Care Teams (MDCTs) in improving outcomes for newly diagnosed breast cancer patients at Hayatabad Medical Complex, Peshawar. The study enrolled 73 participants from May 2021 to April 2024, with follow-up sessions every six months for up to two years.
Participants were randomly assigned to two groups:
Group A (n=37): Received care through MDCTs, which included radiologists, oncologists, and surgeons collaborating to create personalized treatment plans and monitor patient progress.
Group B (n=36): Received standard therapy according to existing institutional protocols.
The study assesses multiple outcomes, including **disease-free survival (DFS), overall survival (OS), recurrence rates, complication rates, patient-reported outcomes (PROs), quality of life (measured via SF-36), and healthcare utilization.
Statistical analyses include Kaplan-Meier survival curves, log-rank tests, Cox proportional hazards regression models, repeated-measures ANOVA, and linear regression models to identify predictors of survival and quality of life.
The study protocol was approved by the Institutional Review Board (IRB) and complies with the Declaration of Helsinki. All participants provided informed consent prior to enrollment.
- Conditions
- Breast Cancers, Breast Cancer Female, Breast Cancer Stage I
- Being tested
- Multidisciplinary Care Team (MDCT) Approach, Standard Breast Cancer Therapy
- Keywords
- Breast Cancer, MDCT, Disease free survival, Quality of life, outcome
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multidisciplinary Care Team (MDCT) ApproachOther
Also called MDCT
A personalized breast cancer treatment plan developed through regular case discussions by a team of radiologists, oncologists, and surgeons. The MDCT coordinates patient support services and tracks treatment progress according to evidence-based guidelines.
Standard Breast Cancer TherapyOther
Also called Standard Therapy
Breast cancer treatment provided according to the institutional protocols at Hayatabad Medical Complex, including standard surgery, chemotherapy, and/or radiotherapy as clinically indicated.
| Study group | Role | What they receive |
|---|---|---|
| MDCT (Group A) | Experimental | Participants receive multidisciplinary care team (MDCT) treatment, including personalized treatment plans developed by oncologists, radiologists, and surgeons. Receives: Other: Multidisciplinary Care Team (MDCT) Approach |
| Standard Therapy (Group B) | Active comparator | Participants receive standard care for breast cancer according to the current institutional protocols. Receives: Other: Standard Breast Cancer Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease-Free Survival (DFS)
Time from the start of treatment to the first occurrence of disease relapse, progression, or death from any cause.
Measured: 24 months (measured at 6, 12, 18, and 24 months)
Overall survival
Time from the start of treatment until death from any cause.
Measured: 24 months (measured at 6, 12, 18, and 24 months)
Secondary outcomes (2)
Recurrence rate
Number of participants with local or distant breast cancer recurrence.
Measured: 24 months (measured at 6, 12, 18, and 24 months)
Complication rate
Incidence of treatment-related complications (e.g., surgical site infections, chemotherapy side effects).
Measured: 24 months (measured at 6, 12, 18, and 24 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2025
- Study start1 May 2021
- Primary completion30 Apr 2024
- Study completion30 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yousaf Jan
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Yousaf Jan, Hayat Abad Medical Complex, Peshawar
- Investigators
- Yousaf Jan, MBBS, FCPS, FRCS, MRCS, ECFMG, Principal investigator, Hayat Abad Medical Complex, Peshawar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06856876
- Sponsor's protocol ID
- HMCKP2
- Acronym
- MDCT
- Status last verified
- Mar 2025
- First submitted
- 26 Feb 2025
- Last updated
- 7 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to share individual participant data (IPD) due to confidentiality concerns and institutional policies.
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Examining the Effectiveness of Multidisciplinary Care Teams in Improving Outcomes for Breast Cancer Patients
- ClinicalTrials.gov ID
- NCT06856876
- Acronym / sponsor ID
- MDCT / HMCKP2
- Conditions
- Breast Cancers, Breast Cancer Female, Breast Cancer Stage I
- Keywords
- Breast Cancer, MDCT, Disease free survival, Quality of life, outcome
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- Yousaf JanOther government
- Study start
- 1 May 2021 (actual)
- Primary completion
- 30 Apr 2024 (actual)
- Study completion
- 30 Apr 2024 (actual)
- First posted
- 4 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare clinical outcomes, patient-reported measures (PROMs), and healthcare utilization between standard care with or without an MDCT in a cohort of women treated for breast cancer.
Detailed description
This single-center, prospective interventional trial evaluates the effectiveness of Multidisciplinary Care Teams (MDCTs) in improving outcomes for newly diagnosed breast cancer patients at Hayatabad Medical Complex, Peshawar. The study enrolled 73 participants from May 2021 to April 2024, with follow-up sessions every six months for up to two years.
Participants were randomly assigned to two groups:
Group A (n=37): Received care through MDCTs, which included radiologists, oncologists, and surgeons collaborating to create personalized treatment plans and monitor patient progress.
Group B (n=36): Received standard therapy according to existing institutional protocols.
The study assesses multiple outcomes, including **disease-free survival (DFS), overall survival (OS), recurrence rates, complication rates, patient-reported outcomes (PROs), quality of life (measured via SF-36), and healthcare utilization.
Statistical analyses include Kaplan-Meier survival curves, log-rank tests, Cox proportional hazards regression models, repeated-measures ANOVA, and linear regression models to identify predictors of survival and quality of life.
The study protocol was approved by the Institutional Review Board (IRB) and complies with the Declaration of Helsinki. All participants provided informed consent prior to enrollment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MDCT (Group A) | Experimental | Other: Multidisciplinary Care Team (MDCT) ApproachParticipants receive multidisciplinary care team (MDCT) treatment, including personalized treatment plans developed by oncologists, radiologists, and surgeons. |
| Standard Therapy (Group B) | Active comparator | Other: Standard Breast Cancer TherapyParticipants receive standard care for breast cancer according to the current institutional protocols. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All female patients, diagnosed with breast cancer
Key exclusion criteria (1 listed)
- Previous treatment for breast cancer, concurrent enrollment in another clinical research, and serious medical conditions that could affect study outcomes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multidisciplinary Care Team (MDCT) ApproachAlso: MDCTA personalized breast cancer treatment plan developed through regular case discussions by a team of radiologists, oncologists, and surgeons. The MDCT coordinates patient support services and tracks treatment progress according to evidence-based guidelines. | Other | MDCT (Group A) |
| Standard Breast Cancer TherapyAlso: Standard TherapyBreast cancer treatment provided according to the institutional protocols at Hayatabad Medical Complex, including standard surgery, chemotherapy, and/or radiotherapy as clinically indicated. | Other | Standard Therapy (Group B) |
Primary outcome
Disease-Free Survival (DFS)
Time frame: 24 months (measured at 6, 12, 18, and 24 months)
Time from the start of treatment to the first occurrence of disease relapse, progression, or death from any cause.
Overall survival
Time frame: 24 months (measured at 6, 12, 18, and 24 months)
Time from the start of treatment until death from any cause.
2 secondary outcomes
Recurrence rate
Time frame: 24 months (measured at 6, 12, 18, and 24 months)
Complication rate
Time frame: 24 months (measured at 6, 12, 18, and 24 months)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2025.
- Individual participant dataSharing planned: No. There is no plan to share individual participant data (IPD) due to confidentiality concerns and institutional policies.
Related trials for Breast Cancers
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yousaf Jan, MBBS, FCPS, FRCS, MRCS, ECFMG principal investigator
Hayat Abad Medical Complex, Peshawar
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multidisciplinary Care Team (MDCT) Approach and Standard Breast Cancer Therapy in people with Breast Cancers and Breast Cancer Female, run by Yousaf Jan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease-Free Survival (DFS) (time frame: 24 months (measured at 6, 12, 18, and 24 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2025; AzTrials last refreshed its copy on 7 Nov 2026.